Jul 15, 2021 7:05am EDT Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada's National Research Council
Jul 05, 2021 8:00am EDT Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets
Jun 15, 2021 7:05am EDT Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs
Jun 07, 2021 7:00am EDT Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1
Jun 03, 2021 7:00am EDT Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus
May 20, 2021 7:05am EDT Lexaria's Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever
